Immuneering Corp (IMRX)vsVertex Pharmaceuticals Inc (VRTX)
IMRX
Immuneering Corp
$4.55
+6.31%
HEALTHCARE · Cap: $285.32M
VRTX
Vertex Pharmaceuticals Inc
$446.83
-1.60%
HEALTHCARE · Cap: $114.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2685274625% more annual revenue ($12.22B vs $455). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
IMRX
Avoid24
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMRX.
Margin of Safety
+52.4%
Fair Value
$949.55
Current Price
$446.83
$502.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IMRX
The strongest argument for IMRX centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : IMRX
The primary concerns for IMRX are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
IMRX profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
IMRX carries more volatility with a beta of 0.38 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 24/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immuneering Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Immuneering Corp (IMRX) is an innovative biotechnology company on the forefront of developing targeted therapeutics for cancer and other serious diseases through its proprietary drug discovery platforms. Utilizing advanced bioinformatics and machine learning techniques, Immuneering is committed to pinpointing and optimizing drug candidates that aim to selectively target critical biological pathways while minimizing toxicity. With a strong portfolio of novel therapies and strategic partnerships, the company is strategically poised to capitalize on the burgeoning fields of personalized medicine and targeted oncology, thereby presenting compelling investment prospects for institutional investors.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?